Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT00182793
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-06-12
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 33
- Registration Number
- NCT00181025
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Wen-Kai Weng
- Target Recruit Count
- 63
- Registration Number
- NCT00185614
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Stem Cell Transplantation for Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 11
- Registration Number
- NCT00176839
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplant for Immunologic or Histiocytic Disorders
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 19
- Registration Number
- NCT00176865
- Locations
- 🇺🇸
Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota, United States
Autologous Transplant for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 363
- Registration Number
- NCT00177047
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00165139
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 481
- Registration Number
- NCT00137995
- Locations
- 🇮🇱
Israel Society of Hematology, Tel-Hashomer, Israel
🇨🇭Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇫🇮Hospital district of south west Finland, Turku, Finland
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00133367
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2012-04-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1
- Registration Number
- NCT00121186
- Locations
- 🇺🇸
Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States
🇺🇸Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States
🇺🇸Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.